Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;39(6):2749-2760.
doi: 10.1007/s12325-022-02100-w. Epub 2022 Apr 15.

Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT

Peter Rieckmann  1   2 , Tjalf Ziemssen  3 , Iris-Katarina Penner  4 , Alaleh Raji  5 , Torsten Wagner  6 , Joachim Richter  6 , Uwe K Zettl  7
Affiliations

Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT

Peter Rieckmann et al. Adv Ther. 2022 Jun.

Abstract

Introduction: Consistent treatment adherence is an important determinant of durable response in multiple sclerosis (MS). Published data indicate that adherence to > 80% of prescribed doses may be considered optimal. Feedback of electronic application monitoring data to patients has been considered a promising means to support high adherence.

Methods: The 2-year prospective non-interventional study REBIFLECT conducted at outpatient neurological centers (731 patients at 134 study sites in Germany) investigated whether treatment adherence to subcutaneous (sc) interferon beta-1 injection during a 1-year period is enhanced by regular physician-patient talks reflecting dosing data recorded by the application device in the context of clinical data or disease parameters. Qualitative adherence was defined as number of weeks with properly distributed injections per total number of weeks with prescribed injections. Quantitative adherence was defined as number of administered injections per prescribed injections.

Results: Overall median qualitative adherence was 90.5%. Approximately 70% of patients with adherence data available in the respective periods had a qualitative treatment adherence of 80-100%. With a mean of 97.9% quantitative adherence was very high and remained stable in the 2-year observation period. The stability of this effect is demonstrated by the subgroup with just one reflection talk (≥ 100%) and only a slight decrease in the subgroup with more than five reflection talks (97.9%).

Conclusion: Treatment adherence with the Rebismart® device was generally very high, consistent with other non-interventional studies. The first reflection talk supported by RebiSmart® induces excellent adherence, stabilized by repetition. Reflection to patients of subcutaneous interferon beta-1a treatment monitored by RebiSmart® is recommended to ensure prolonged strong treatment adherence.

Keywords: Adherence; Feedback; Injector; Interferon beta-1a sc; REBIFLECT; Rebif®; Rebismart®; Reflection.

PubMed Disclaimer

References

    1. Sabaté E. Adherence to long-term therapies. Evidence for action. World Health Organization. 2003. http://apps.who.int/medicinedocs/pdf/s4883e/s4883e.pdf. Accessed 21 Mar 2022.
    1. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255(Suppl 6):87–92.eo. doi: 10.1007/s00415-008-6016-8. - DOI - PubMed
    1. Kern S, Reichmann H, Ziemssen T. Therapieadhärenz in der neurologischen Praxis [Treatment adherence in neurological practice] Nervenarzt. 2008;79:877–890. doi: 10.1007/s00115-008-2419-0. - DOI - PubMed
    1. Evans C, Marrie RA, Zhu F, et al. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations: MS adherence and hospitalizations. Pharmacoepidemiol Drug Saf. 2017;26:702–711. doi: 10.1002/pds.4207. - DOI - PubMed
    1. Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res. 2017;9:251–260. doi: 10.2147/CEOR.S130334. - DOI - PMC - PubMed

Publication types

MeSH terms